



IPW

Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TERMINAL DISCLAIMER TO OBTAIN A DOUBLE PATENTING
REJECTION OVER A PRIOR PATENT**

Docket Number (Optional)

CELLTH 3.0-003 CONT CONT IX

In re Application of: Raymond P. Warrell, Jr., Pier Paolo Pandolfi, and Janice L. Gabrilove

Application No.: 10/758,800

Filed: January 16, 2004

For: **PROCESS FOR PRODUCING ARSENIC TRIOXIDE FORMULATIONS AND METHODS FOR
TREATING CANCER USING ARSENIC TRIOXIDE OR MELASOPROL**

The owner*, Memorial Sloan-Kettering Cancer Center, of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 and 173, as presently shortened by any terminal disclaimer, of prior Patent No. 6,723,351. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

Check either box 1 or 2 below, if appropriate.

1. ☐ For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

2. ☒ The undersigned is an attorney or agent of record.

Shawn P. Foley
Signature

August 31, 2004

Date

Shawn P. Foley - 33,071

Typed or printed name

- ☒ The Commissioner is hereby authorized to charge the Terminal disclaimer fee under 37 CFR 1.20(d) to Deposit Account No. 12-1095

LD-544: *Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner).
Form PTO/SB/96 may be used for making this certification. See MPEP § 324.

512377_1.DOC

09/02/2004 SZWDIE1 00000082 121095 10758800

01 FC:1814 110.00 DA

87

JFW
#

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TERMINAL DISCLAIMER TO OBTAIN A PROVISIONAL DOUBLE PATENTING
REJECTION OVER A PENDING SECOND APPLICATION**

Docket Number (Optional)

CELLLT 3.0-003 CONT CONT IX

In re Application of: Raymond P. Warrell, Jr., Pier Paolo Pandolfi, and Janice L. Gabrilove

Application No.: 10/758,800

Filed: January 16, 2004

For: **PROCESS FOR PRODUCING ARSENIC TRIOXIDE FORMULATIONS AND METHODS FOR
TREATING CANCER USING ARSENIC TRIOXIDE OR MELARSOPROL**

The owner*, Memorial Sloan-Kettering Cancer Center, of 100

percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173 as shortened by any terminal disclaimer filed prior to the grant of any patent granted on the following pending related applications:

10/758,993 filed on January 16, 2004
10/758,994 filed on January 16, 2004
10/758,995 filed on January 16, 2004
10/758,996 filed on January 16, 2004
10/759,290 filed on January 16, 2004
10/759,291 filed on January 16, 2004
10/759,293 filed on January 16, 2004
10/759,308 filed on January 16, 2004

10/759,313 filed on January 16, 2004
10/759,314 filed on January 16, 2004
10/759,439 filed on January 16, 2004
10/759,616 filed on January 16, 2004
10/759,657 filed on January 16, 2004
10/759,716 filed on January 16, 2004
10/759,726 filed on January 16, 2004
10/759,882 filed on January 16, 2004

of any patent on the above-listed pending related applications. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on the above-listed pending related applications are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of any patent granted on the above-listed pending applications, as shortened by any terminal disclaimer filed prior to the patent grant, in the event that any such granted patent: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.

Check either box 1 or 2 below, if appropriate.

1. ☐ For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

2. ☒ The undersigned is an attorney or agent of record.

Shawn P. Foley August 31, 2004
Signature Date

Shawn P. Foley - 33,071
Typed or printed name

- ☒ The Commissioner is hereby authorized to charge the disclaimer fee under 37 CFR 1.20(d) to
Deposit Account No. 12-1095

LD-543/512376_1.DOC